AR061107A1 - Anticuerpos bloqueantes de la funcion de la integrina (alfa)5(beta)1 humanos y humanizados de gran afinidad con inmunogenicidad reducida - Google Patents
Anticuerpos bloqueantes de la funcion de la integrina (alfa)5(beta)1 humanos y humanizados de gran afinidad con inmunogenicidad reducidaInfo
- Publication number
- AR061107A1 AR061107A1 ARP070102226A ARP070102226A AR061107A1 AR 061107 A1 AR061107 A1 AR 061107A1 AR P070102226 A ARP070102226 A AR P070102226A AR P070102226 A ARP070102226 A AR P070102226A AR 061107 A1 AR061107 A1 AR 061107A1
- Authority
- AR
- Argentina
- Prior art keywords
- humanized
- integrin
- human
- antibody
- function
- Prior art date
Links
- 102000006495 integrins Human genes 0.000 title abstract 4
- 108010044426 integrins Proteins 0.000 title abstract 4
- 230000000903 blocking effect Effects 0.000 title 1
- 230000005847 immunogenicity Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000000975 dye Substances 0.000 abstract 1
- 239000007850 fluorescent dye Substances 0.000 abstract 1
- 238000001215 fluorescent labelling Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000002372 labelling Methods 0.000 abstract 1
- 230000002285 radioactive effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Abstract
Polipéptidos recombinantes humanos o humanizados que se unen a la integrina alfa5beta1 con gran afinidad y bloquean su funcion. Además, se describen aplicaciones de diagnostico y farmacéutico de los polipéptidos Reivindicacion 1: Un anticuerpo humano o humanizado, o un fragmento de union al antígeno del mismo, que se une a la integrina alfa5beta1 con una afinidad <=100 nM y que inhibe la adhesion de las células que expresan integrina alfa5beta1 a su receptor in vitro e in vivo. Reivindicacion 21: El anticuerpo, o fragmento de anticuerpo, de cualquiera de las reivindicaciones 1-17 en la forma de un polipéptido de fusion. Reivindicacion 24: El anticuerpo, o fragmento de anticuerpo, de la reivindicacion 23, en donde el grupo de marcacion detectable se selecciona entre grupos de marcacion radioactivos, NMR, colorantes, enzimas y fluorescentes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06010779 | 2006-05-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061107A1 true AR061107A1 (es) | 2008-08-06 |
Family
ID=38659612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102226A AR061107A1 (es) | 2006-05-24 | 2007-05-23 | Anticuerpos bloqueantes de la funcion de la integrina (alfa)5(beta)1 humanos y humanizados de gran afinidad con inmunogenicidad reducida |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20090081207A1 (es) |
| EP (1) | EP2032605A2 (es) |
| JP (1) | JP2009537158A (es) |
| KR (1) | KR20090027218A (es) |
| CN (1) | CN101495515A (es) |
| AR (1) | AR061107A1 (es) |
| AU (1) | AU2007253586A1 (es) |
| BR (1) | BRPI0711796A2 (es) |
| CA (1) | CA2652886A1 (es) |
| CL (1) | CL2007001488A1 (es) |
| CR (1) | CR10456A (es) |
| DO (2) | DOP2007000101A (es) |
| EA (1) | EA200802348A1 (es) |
| EC (1) | ECSP088909A (es) |
| MA (1) | MA30425B1 (es) |
| MX (1) | MX2008014910A (es) |
| NO (1) | NO20085362L (es) |
| PE (1) | PE20080100A1 (es) |
| TN (1) | TNSN08469A1 (es) |
| TW (1) | TW200817433A (es) |
| UY (1) | UY30362A1 (es) |
| WO (1) | WO2007134876A2 (es) |
| ZA (1) | ZA200810850B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2481756T3 (en) | 2005-10-31 | 2017-10-09 | Oncomed Pharm Inc | Compositions and Methods for Diagnosing and Treating Cancer |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| EP1989231B1 (en) | 2006-03-21 | 2015-05-20 | Genentech, Inc. | Combinatorial therapy involving alpha5beta1 antagonists |
| PE20091029A1 (es) | 2007-09-26 | 2009-08-19 | Genentech Inc | Anticuerpos anti-alfa 5 beta 1 |
| CA2714071A1 (en) * | 2008-02-05 | 2009-08-13 | Bristol-Myers Squibb Company | Alpha 5 - beta 1 antibodies and their uses |
| CN105079805A (zh) | 2008-09-26 | 2015-11-25 | 昂考梅德药品有限公司 | 卷曲蛋白结合药剂及其应用 |
| EP2356154A4 (en) * | 2008-11-06 | 2012-12-19 | Alexion Pharma Inc | DEVELOPMENT OF REDUCED IMMUNOGENICITY ANTIBODIES AND METHODS OF MANUFACTURING THEREOF |
| AU2009331528A1 (en) * | 2008-12-23 | 2011-08-11 | Astrazeneca Ab | Targeted binding agents directed to alpha5beta1 and uses thereof |
| NZ594343A (en) | 2009-03-25 | 2013-10-25 | Genentech Inc | Novel anti-alpha5beta1 antibodies and uses thereof |
| GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| NZ602700A (en) | 2010-04-01 | 2014-10-31 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
| ES2540114T3 (es) * | 2010-07-09 | 2015-07-08 | Affibody Ab | Polipéptidos |
| UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
| EP2545905A1 (en) | 2011-07-11 | 2013-01-16 | Britannia Pharmaceuticals Limited | A new therapeutical composition containing apomorphine as active ingredient |
| TWI586378B (zh) | 2012-03-13 | 2017-06-11 | 瑞斯比維特有限公司 | 新穎醫藥調配物 |
| WO2014066328A1 (en) | 2012-10-23 | 2014-05-01 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using wnt pathway-binding agents |
| MX2015008534A (es) * | 2012-12-26 | 2017-07-04 | Oncosynergy Inc | COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS. |
| AU2014212081A1 (en) | 2013-02-04 | 2015-08-13 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a Wnt pathway inhibitor |
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| CA2987884C (en) * | 2015-06-28 | 2023-01-03 | Allgenesis Biotherapeutics Inc. | Fusion peptides comprising disintegrin binding to integrin .alpha.v.beta.x or .alpha.5.beta.1 and their use in treating an angiogenic disease |
| US12383634B2 (en) * | 2019-07-24 | 2025-08-12 | Korea Basic Science Institute | Single domain antibody targeting αVβ3 integrin |
| US11723955B1 (en) | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6013495A (en) * | 1994-10-21 | 2000-01-11 | The Scripps Research Institute | Methods of use for integrin B1C cell growth inhibitor |
| US6852318B1 (en) * | 1998-05-08 | 2005-02-08 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
| US7276589B2 (en) * | 2002-11-26 | 2007-10-02 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
| US7285268B2 (en) * | 2002-11-26 | 2007-10-23 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
| NZ540562A (en) * | 2002-11-26 | 2008-04-30 | Pdl Biopharma Inc | Therapeutic chimeric and humanized antibodies directed against alpha5beta1 integrin, methods for purification of these antibodies, and their use in treating conditions comprising undesirable tissue angiogenesis |
| WO2005092073A2 (en) * | 2004-03-24 | 2005-10-06 | Pdl Biopharma, Inc. | Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation |
| EP1989231B1 (en) * | 2006-03-21 | 2015-05-20 | Genentech, Inc. | Combinatorial therapy involving alpha5beta1 antagonists |
-
2007
- 2007-05-21 EP EP07725544A patent/EP2032605A2/en not_active Withdrawn
- 2007-05-21 AU AU2007253586A patent/AU2007253586A1/en not_active Abandoned
- 2007-05-21 JP JP2009511419A patent/JP2009537158A/ja active Pending
- 2007-05-21 BR BRPI0711796-5A patent/BRPI0711796A2/pt not_active IP Right Cessation
- 2007-05-21 CN CNA2007800265176A patent/CN101495515A/zh active Pending
- 2007-05-21 WO PCT/EP2007/004648 patent/WO2007134876A2/en not_active Ceased
- 2007-05-21 MX MX2008014910A patent/MX2008014910A/es not_active Application Discontinuation
- 2007-05-21 KR KR1020087031278A patent/KR20090027218A/ko not_active Withdrawn
- 2007-05-21 CA CA002652886A patent/CA2652886A1/en not_active Abandoned
- 2007-05-21 EA EA200802348A patent/EA200802348A1/ru unknown
- 2007-05-22 DO DO2007000101A patent/DOP2007000101A/es unknown
- 2007-05-22 UY UY30362A patent/UY30362A1/es not_active Application Discontinuation
- 2007-05-22 DO DO2007P000101A patent/DOP20070101A/es unknown
- 2007-05-23 US US11/802,573 patent/US20090081207A1/en not_active Abandoned
- 2007-05-23 AR ARP070102226A patent/AR061107A1/es unknown
- 2007-05-23 PE PE2007000634A patent/PE20080100A1/es not_active Application Discontinuation
- 2007-05-24 CL CL2007001488A patent/CL2007001488A1/es unknown
- 2007-05-24 TW TW096118587A patent/TW200817433A/zh unknown
-
2008
- 2008-11-20 TN TNP2008000469A patent/TNSN08469A1/en unknown
- 2008-11-21 MA MA31403A patent/MA30425B1/fr unknown
- 2008-11-24 EC EC2008008909A patent/ECSP088909A/es unknown
- 2008-11-24 CR CR10456A patent/CR10456A/es not_active Application Discontinuation
- 2008-12-22 NO NO20085362A patent/NO20085362L/no not_active Application Discontinuation
- 2008-12-23 ZA ZA200810850A patent/ZA200810850B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200817433A (en) | 2008-04-16 |
| DOP20070101A (es) | 2007-12-30 |
| KR20090027218A (ko) | 2009-03-16 |
| PE20080100A1 (es) | 2008-04-18 |
| JP2009537158A (ja) | 2009-10-29 |
| WO2007134876A8 (en) | 2009-07-02 |
| DOP2007000101A (es) | 2007-12-31 |
| ZA200810850B (en) | 2010-05-26 |
| ECSP088909A (es) | 2008-12-30 |
| MA30425B1 (fr) | 2009-05-04 |
| CA2652886A1 (en) | 2007-11-29 |
| CN101495515A (zh) | 2009-07-29 |
| WO2007134876A3 (en) | 2008-03-27 |
| AU2007253586A1 (en) | 2007-11-29 |
| CL2007001488A1 (es) | 2008-01-04 |
| US20090081207A1 (en) | 2009-03-26 |
| BRPI0711796A2 (pt) | 2011-12-06 |
| EA200802348A1 (ru) | 2009-08-28 |
| WO2007134876A2 (en) | 2007-11-29 |
| EP2032605A2 (en) | 2009-03-11 |
| MX2008014910A (es) | 2009-01-23 |
| UY30362A1 (es) | 2008-01-02 |
| TNSN08469A1 (en) | 2010-04-14 |
| NO20085362L (no) | 2009-02-23 |
| CR10456A (es) | 2009-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061107A1 (es) | Anticuerpos bloqueantes de la funcion de la integrina (alfa)5(beta)1 humanos y humanizados de gran afinidad con inmunogenicidad reducida | |
| AR076797A1 (es) | Anticuerpos triespecificos o tetraespecificos | |
| CL2021001986A1 (es) | Anticuerpos y receptores quiméricos de antígenos específicos para receptor 1 huérfano tipo receptor tirosina-cinasa (ror1). | |
| PE20140218A1 (es) | Composicion farmaceutica | |
| ES2525477T3 (es) | Anticuerpos anti-factor D humanizados | |
| UY29770A1 (es) | Polipéptidos y anticuerpos | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| AR047729A1 (es) | Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe) | |
| DOP2013000045A (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| AR077088A1 (es) | Proteinas biespecificas de union a antigeno | |
| UY31433A1 (es) | Nuevos anticuerpos especificos de los peptidos - amiloides y sus usos como agentes de diagnostico o drogas | |
| CO6290705A2 (es) | Anticuerpos monoclonales aislados o porciones de union a antigenos, que se unen especificamente a la integrina alfa 5-beta1, y composiciones farmaceuticamente aceptables de los mismos | |
| ATE178097T1 (de) | Monoklonale antikörper gegen den alpha-pdgf- rezeptor und deren verwendungen | |
| AR073538A1 (es) | Anticuerpos multiespecificos que se unen especificamente al receptor del factor de crecimiento epidermico humano 2 (her2) y al factor de crecimiento endotelial vascular (vegf) | |
| AR077111A1 (es) | Proteinas biespecificas tetravalentes de union a antigeno | |
| Liang et al. | Allosteric regulation of fibronectin/α5β1 interaction by fibronectin-binding MSCRAMMs | |
| CO6231040A2 (es) | Moleculas y metodos para modular la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) | |
| ATE497508T1 (de) | Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper | |
| JP2014113150A5 (es) | ||
| PE20180502A1 (es) | Composiciones anti-cgrp y uso de las mismas | |
| PE20090368A1 (es) | Anticuerpos anti-igf | |
| UY31123A1 (es) | Proteinas de fusion natriureticas | |
| RU2018141360A (ru) | Contorsbody - одноцепочечный связывающий мишень агент | |
| JP2013511966A5 (es) | ||
| EA201590459A1 (ru) | Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |